Key result
Metabolic syndrome in CHF is linked to ~55% higher rates of pronounced damage markers.
Why the study?
Metabolic syndrome significantly increases cardiovascular disease risk leading to CHF, but the features of marker changes (NT-proBNP, ST-2, CRP) in CHF complicated by metabolic syndrome needed determination.
Do laboratory markers (NT-proBNP, ST-2, CRP) differ between CHF patients with and without metabolic syndrome, and do they predict outcomes?
Observational (n=74)
Do laboratory markers (NT-proBNP, ST-2, CRP) differ between CHF patients with and without metabolic syndrome, and do they predict outcomes?
A combined ranking of NT-proBNP, ST-2, and CRP levels is higher in CHF patients with metabolic syndrome and may serve as a predictor of hospitalization outcomes, including mortality.
May signal higher risk in CHF with metabolic syndrome; hypothesis-generating for marker-based outcome prediction.
The presence of metabolic syndrome (MS) significantly increases the risk of developing cardiovascular diseases that lead to chronic heart failure (CHF). The values of NT-proBNP, ST-2, and CRP markers and their mutual correlations were studied in 37 patients with chronic heart failure (CHF) without metabolic syndrome (MS) (group 1) and 37 patients with CHF with MS (group 2). The aim of the study was to determine the features of their changes in patients with CHF complicated by MS, and to rank patients by assigning a rank value to the values of NTproBNP, ST2, and CRP concentrations. The average ST2 level was 51±24 ng/ml in group 1 and 62±27 ng/ml in group 2. The average values of CRP in group 1 were 23.1±5.3 mg/l, in group 2-33.0±4.4 mg/l (p<0.05). The NTproBNP level was 2413±1586 PG/ml and 2721±1635 PG/ml in groups 1 and 2, respectively. Correlations between the values of NTproBNP and ST2, NTproBNP and CRP were demonstrated. In the group of CHF with MS, compared with the group of CHF, there were significantly more patients with the most pronounced pathological levels of damage markers: the number of patients with a General rank of 6-9 in the group of CHF with MS was 59%, in the group of CHF without MS-38% (p<0.05). Of the 18 patients who died, 17 were among those who had an overall rank of 6 to 9, only 1 patient who died after hospitalization had an overall rank of 5. At the same time, among 22 patients who had improved CHF in the outcome of hospitalization, 18 patients had a total rank from 0 to 5, and in 4 patients of this category, the clinical manifestations of CHF remained virtually unchanged. The results of ranking the level of the studied laboratory markers indicate that they can be used as a predictor of various outcomes of CHF.
No takes yet. Share an insight, caveat, or question.
Roytman et al. (2021) conducted an observational in Chronic heart failure with metabolic syndrome (n=74). Metabolic syndrome vs. No metabolic syndrome was evaluated on General rank of 6-9 for damage markers (NTproBNP, ST2, CRP) (p=<0.05). Chronic heart failure patients with metabolic syndrome had significantly higher rates of pronounced pathological damage marker levels than those without metabolic syndrome (59% vs 38%, p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: